| Literature DB >> 32114427 |
Vijay Viswanathan1, Ankush D Jamthikar2, Deep Gupta2, Nizarudeen Shanu3, Anudeep Puvvula4, Narendra N Khanna5, Luca Saba6, Tomaz Omerzum7, Klaudija Viskovic8, Sophie Mavrogeni9, Monika Turk10, John R Laird11, Gyan Pareek12, Martin Miner13, Petros P Sfikakis14, Athanasios Protogerou15, George D Kitas16, Chitra S17, Shalini Joshi18, Henreitta Fiscian19, Aba Ankomaba Folson20, Dee H Wu21, Zoltan Ruzsa22, Andrew Nicolaides23, Aditya Sharma24, Deepak L Bhatt25, Jasjit S Suri26.
Abstract
Diabetes and atherosclerosis are the predominant causes of stroke and cardiovascular disease (CVD) both in low- and high-income countries. This is due to the lack of appropriate medical care or high medical costs. Low-cost 10-year preventive screening can be used for deciding an effective therapy to reduce the effects of atherosclerosis in diabetes patients. American College of Cardiology (ACC)/American Heart Association (AHA) recommended the use of 10-year risk calculators, before advising therapy. Conventional risk calculators are suboptimal in certain groups of patients because their stratification depends on (a) current blood biomarkers and (b) clinical phenotypes, such as age, hypertension, ethnicity, and sex. The focus of this review is on risk assessment using innovative composite risk scores that use conventional blood biomarkers combined with vascular image-based phenotypes. AtheroEdge™ tool is beneficial for low-moderate to high-moderate and low-risk to high-risk patients for the current and 10-year risk assessment that outperforms conventional risk calculators. The preventive screening tool that combines the image-based phenotypes with conventional risk factors can improve the 10-year cardiovascular/stroke risk assessment.Entities:
Mesh:
Year: 2020 PMID: 32114427 DOI: 10.2741/4850
Source DB: PubMed Journal: Front Biosci (Landmark Ed) ISSN: 2768-6698